臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

???ui.leftmenu.abouttair???
	???ui.leftmenu.explanation???

???ui.leftmenu.bartitle???
	Repositories
	Author
	Title
	Date
	???ui.leftmenu.statisticschart???
	???ui.leftmenu.realtimefacts???
	???ui.leftmenu.trend???

???index.news???
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

???ui.leftmenu.copyrighttitle???
	???ui.leftmenu.copyrightpublisher???
	???ui.leftmenu.copyrightconference???

???ui.leftmenu.link???
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"yang s s"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1???	???jsp.browse.items-by-author.order2???

Showing items 151-200 of 585 (12 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page

Institution	Date	Title	Author
臺大學術典藏	2021-07-03T03:33:36Z	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study	Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Hung C.-C.; Kao J.-H.
臺大學術典藏	2021-07-03T03:33:31Z	Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis	Liu C.-H.;Shih Y.-L.;Yang S.-S.;Lin C.-L.;Fang Y.-J.;Cheng P.-N.;Chen C.-Y.;Peng C.-Y.;Hsieh T.-Y.;Chiu Y.-C.;Su T.-H.;Liu C.-J.;Yang H.-C.;Pei-Jer Chen;Chen D.-S.;Kao J.-H.; Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; Liu C.-J.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-07-03T03:33:26Z	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment	Liu C.-H.; Yang S.-S.; Peng C.-Y.; Lin W.-T.; Liu C.-J.; Su T.-H.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-07-03T03:33:21Z	High risk of clinical relapse in patients with chronic Hepatitis B virus infection after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy	Chang W.-Y.; Chiu Y.-C.; Chiu F.-W.; Hsu Y.-C.; Tseng T.-C.; Cheng P.-N.; Yang S.-S.; Liu C.-J.; Su T.-H.; Yang H.-C.; Liu C.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-07-03T03:33:20Z	Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis	Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-06-25T08:10:14Z	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study	Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; Su T.-H.; Yang H.-C.; CHUN-MING HONG; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; Kao J.-H.
臺大學術典藏	2021-06-15T03:12:12Z	Reduced Toll-like receptor 3 expression in chronic hepatitis B patients and its restoration by interferon therapy	Huang Y.-W.; Lin S.-C.; SHU-CHEN WEI; Hu J.-T.; Chang H.-Y.; Huang S.-H.; Chen D.-S.; Chen P.-J.; Hsu P.-N.; Yang S.-S.; Kao J.-H.
臺大學術典藏	2021-06-15T03:12:11Z	Reduced toll-like receptor 9 expression on peripheral C D14+ monocytes of chronic hepatitis B patients and its restoration by effective therapy	Huang Y.-W.; Hsu C.-K.; Lin S.-C.; SHU-CHEN WEI; Hu J.-T.; Chang H.-Y.; Liang C.-W.; Chen D.-S.; Chen P.-J.; Hsu P.-N.; Yang S.-S.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:53Z	Pegylated interferon-α-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial	CHEN-HUA LIU; Liu C.-J.; Lin C.-.; Liang C.-C.; Hsu S.-J.; Yang S.-S.; Hsu C.-S.; Tseng T.-C.; Wang C.-C.; Lai M.-Y.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:50Z	HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses	Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; CHEN-HUA LIU; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S.
臺大學術典藏	2021-05-24T07:20:49Z	Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy	Tseng T.-C.; Yu M.-L.; Liu C.-J.; Lin C.-L.; Huang Y.-W.; Hsu C.-S.; CHEN-HUA LIU; Kuo S.F.-T.; Pan C.J.-H.; Yang S.-S.; Su C.-W.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:46Z	Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin	CHEN-HUA LIU; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:46Z	Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy	CHEN-HUA LIU; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Hsu S.-J.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:44Z	Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up	Yu M.-L.; Lee C.-M.; Chen C.-L.; Chuang W.-L.; Lu S.-N.; CHEN-HUA LIU; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Kao J.-H.; Su W.-W.; Lin C.-L.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Liu C.-J.
臺大學術典藏	2021-05-24T07:20:40Z	Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: A randomized trial	CHEN-HUA LIU; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Chen S.-I.; Lin J.-W.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:34Z	Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial	CHEN-HUA LIU; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Lee C.-Y.; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:34Z	Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial	CHEN-HUA LIU; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Kao J.-H.; Yu M.-L.
臺大學術典藏	2021-05-24T07:20:33Z	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial	CHEN-HUA LIU; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Kao J.-H.; Yu M.-L.
臺大學術典藏	2021-05-24T07:20:26Z	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study	CHEN-HUA LIU; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:21Z	Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis	CHEN-HUA LIU; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:20Z	Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment	CHEN-HUA LIU; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; Liu C.-J.; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; Fang Y.-J.; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:18Z	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment	CHEN-HUA LIU; Yang S.-S.; Peng C.-Y.; Lin W.-T.; Liu C.-J.; Su T.-H.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:15Z	High risk of clinical relapse in patients with chronic Hepatitis B virus infection after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy	Chang W.-Y.; Chiu Y.-C.; Chiu F.-W.; Hsu Y.-C.; Tseng T.-C.; Cheng P.-N.; Yang S.-S.; Liu C.-J.; Su T.-H.; Yang H.-C.; CHEN-HUA LIU; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:14Z	Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis	CHEN-HUA LIU; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:13Z	Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan	CHEN-HUA LIU; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; Hung C.-C.; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?�Y.; Kao J.-H.
臺大學術典藏	2021-05-24T07:20:12Z	Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan	Chen C.-Y.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Lo C.-C.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU; Lee M.-H.; Liu C.-J.; Dai C.-Y.; Kao J.-H.; Chuang W.-L.; Lin H.-C.; Yu M.-L.
臺大學術典藏	2021-05-06T01:25:13Z	Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan	Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; CHIEN-CHING HUNG; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?Y.; Kao J.-H.
臺大學術典藏	2021-03-15T07:59:46Z	Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus	Huang Y.-W.; CHUNG-YI HU; Chen C.-L.; Liao Y.-T.; Liu C.-J.; Lai M.-Y.; Chen P.-J.; Yang S.-S.; Hu J.-T.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:46Z	HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses	Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; Liu C.-H.; TUNG-HUNG SU; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S.
臺大學術典藏	2021-03-09T01:47:46Z	Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin	Liu C.-H.; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; TUNG-HUNG SU; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:46Z	Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy	Liu C.-H.; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; TUNG-HUNG SU; Hsu S.-J.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:41Z	Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: A randomized trial	Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Chen S.-I.; Lin J.-W.; Yang S.-S.; TUNG-HUNG SU; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:36Z	Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial	Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; TUNG-HUNG SU; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Kao J.-H.; Yu M.-L.
臺大學術典藏	2021-03-09T01:47:35Z	Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial	Liu C.-H.; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Lee C.-Y.; Chen S.-I.; Yang S.-S.; TUNG-HUNG SU; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:35Z	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial	Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; TUNG-HUNG SU; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Kao J.-H.; Yu M.-L.
臺大學術典藏	2021-03-09T01:47:33Z	Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan	Wang C.-C.; Lin C.-L.; Hsieh T.-Y.; Tseng K.-C.; Peng C.-Y.; TUNG-HUNG SU; Yang S.-S.; Hsu Y.-C.; Chen T.-M.; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:32Z	Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients	TUNG-HUNG SU; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; Chen C.-L.; Kao J.-H.; the C-TEAM study group; the Taiwan Liver Diseases Consortium
臺大學術典藏	2021-03-09T01:43:20Z	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study	Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; TUNG-HUNG SU; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; Kao J.-H.
臺大學術典藏	2021-03-09T01:43:16Z	Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis	Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; TUNG-HUNG SU; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-03-09T01:43:12Z	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment	Liu C.-H.; Yang S.-S.; Peng C.-Y.; Lin W.-T.; Liu C.-J.; TUNG-HUNG SU; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-03-09T01:43:10Z	High risk of clinical relapse in patients with chronic Hepatitis B virus infection after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy	Chang W.-Y.; Chiu Y.-C.; Chiu F.-W.; Hsu Y.-C.; Tseng T.-C.; Cheng P.-N.; Yang S.-S.; Liu C.-J.; TUNG-HUNG SU; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-03-09T01:43:09Z	Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis	Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; TUNG-HUNG SU; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-02-23T08:26:42Z	Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma	Chen L.-T.;Lin J.-T.;Tai J.J.;Chen G.-H.;Yeh H.-Z.;Yang S.-S.;Wang H.-P.;Sung-Hsin Kuo;Sheu B.-S.;Jan C.-M.;Wang W.-M.;Wang T.-E.;Wu C.-W.;Chen C.-L.;Su I.-J.;Whang-Peng J.;Cheng A.-L.; Chen L.-T.; Lin J.-T.; Tai J.J.; Chen G.-H.; Yeh H.-Z.; Yang S.-S.; Wang H.-P.; SUNG-HSIN KUO; Sheu B.-S.; Jan C.-M.; Wang W.-M.; Wang T.-E.; Wu C.-W.; Chen C.-L.; Su I.-J.; Whang-Peng J.; Cheng A.-L.
臺大學術典藏	2021-02-18T08:01:13Z	Safety of perfluorobutane (Sonazoid) in characterizing focal liver lesions	Chou Y.-H.; JA-DER LIANG; Wang S.-Y.; Hsu S.-J.; Hu J.-T.; Yang S.-S.; Wang H.-K.; Lee T.-Y.; Tiu C.-M.
臺大學術典藏	2021-02-03T03:56:43Z	Lower urinary tract symptoms in women with irritable bowel syndrome: Original Article: Clinical Investigation	Guo Y.-J.; Ho C.-H.; Chen S.-C.; Yang S.-S.; HAN-MO CHIU; Huang K.-H.
臺大學術典藏	2021-02-02T02:48:03Z	Reduced Toll-like receptor 3 expression in chronic hepatitis B patients and its restoration by interferon therapy	Huang Y.-W.; Lin S.-C.; Wei S.-C.; Hu J.-T.; Chang H.-Y.; Huang S.-H.; Chen D.-S.; Chen P.-J.; PING-NING HSU; Yang S.-S.; Kao J.-H.
臺大學術典藏	2021-02-02T02:48:02Z	Reduced toll-like receptor 9 expression on peripheral C D14+ monocytes of chronic hepatitis B patients and its restoration by effective therapy	Huang Y.-W.; Hsu C.-K.; Lin S.-C.; Wei S.-C.; Hu J.-T.; Chang H.-Y.; Liang C.-W.; Chen D.-S.; Chen P.-J.; PING-NING HSU; Yang S.-S.; Kao J.-H.
臺大學術典藏	2021-02-02T00:43:01Z	Assessment of ketamine uropathy	Yang S.S.;Wu C.-H.;Chen J.Y.J.;Chang S.-J.;Jang M.Y.;Wu W.J.;Ruan Y.S.;Li S.Y.;Wu J.S.;Chung Y.C.;Li W.J.;Li Y.H.;Tang Y.C.;Shen K.H.;Lin W.Y.;Chen J.S.;Lee M.H.;Chen M.H.;Zou J.L.;Jhang J.S.;Syu J.S.;Yang S.S.;Chang S.J.;Lin A.T.L.;Fan Y.H.;Meng E.;Syu Y.J.;Hong-Jeng Yu;Guo Y.C.;Ye J.S.;Wang Y.J.;Jhang J.F.;Jiang Y.H.;Kuo H.C.;Team For National Registration Of Ketamine Uropathy; Yang S.S.; Wu C.-H.; Chen J.Y.J.; Chang S.-J.; Jang M.Y.; Wu W.J.; Ruan Y.S.; Li S.Y.; Wu J.S.; Chung Y.C.; Li W.J.; Li Y.H.; Tang Y.C.; Shen K.H.; Lin W.Y.; Chen J.S.; Lee M.H.; Chen M.H.; Zou J.L.; Jhang J.S.; Syu J.S.; Yang S.S.; Chang S.J.; Lin A.T.L.; Fan Y.H.; Meng E.; Syu Y.J.; HONG-JENG YU; Guo Y.C.; Ye J.S.; Wang Y.J.; Jhang J.F.; Jiang Y.H.; Kuo H.C.; Team for National Registration of Ketamine Uropathy
臺大學術典藏	2021-01-28T02:03:42Z	Lower urinary tract symptoms in women with irritable bowel syndrome: Original Article: Clinical Investigation	Guo Y.-J.;Ho C.-H.;Chen S.-C.;Yang S.-S.;Chiu H.-M.;Kuo-How Huang; Guo Y.-J.; Ho C.-H.; Chen S.-C.; Yang S.-S.; Chiu H.-M.; KUO-HOW HUANG
臺大學術典藏	2021-01-15T03:47:46Z	Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma	Chen L.-T.; Lin J.-T.; Tai J.J.; Chen G.-H.; Yeh H.-Z.; Yang S.-S.; HSIU-PO WANG; Kuo S.-H.; Sheu B.-S.; Jan C.-M.; Wang W.-M.; Wang T.-E.; Wu C.-W.; Chen C.-L.; Su I.-J.; Whang-Peng J.; Cheng A.-L.

Showing items 151-200 of 585 (12 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page

	English \| 正體中文 \| 简体中文 \| 2856704
	???header.visitor??? : 53698493 ???header.onlineuser??? : 2005 ???header.sponsordeclaration???